Dicot's business concept is to develop the product Libiguin® as a drug for treating sexual dysfunctions. The development takes place on its own up to clinical phases.

Press release
17 July, 2020

Disclosure Notice - Major shareholding notification

Press release: Uppsala, July 17, 2020. Dicot AB (publ) ("Dicot" or the "Company") announces today, July 17, the following disclosure notice as a result of the Company's completed rights issue.

Press release
8 July, 2020

Adjustments of warrants of series 2019/2020

Press release: Uppsala, July 8 2020. Dicot AB (publ) ("Dicot") will, in accordance with the terms for the warrants 2019/2020, carry out a recalculation in accordance with the warrant terms as a result of the latest completed rights issue of units pub...

Press release
7 July, 2020

Dicot resolves on a directed issue of shares (compensation issue) to guarantors in conjunction with the oversubscribed rights issue

Press release: Uppsala, July 7, 2020. Dicot AB ("Dicot" or the "Company") has completed the rights issue of units amounting to SEK 21.8 million, which was disclosed on April 23, 2020 and resolved by the annual general meeting on May 26, 2020 (the "Ri...

"Lust and joy for life"

With the motto "Lust and joy for life," the company's strategy is to develop Libiguin® up to clinical phase II, after which the company plans to partner with a major pharmaceutical company to be able to take Libiguin® to registered drug distintion and introduce Libiguin® to the global market.

The goal is Libiguin® to become the first-choice treatment for the treatment of erectile dysfunction (ED) and premature ejaculation (PE) and to take a predominant market share for the treatment of patients in those indications.

Watch CEO Göran Beijer presenting the company:

Contact us

Dicot AB
Dag Hammarskjölds Väg 30
SE-752 37 Uppsala SWEDEN
+46 (0) 70-663 60 09
info@dicot.se

The information is processed according to our privacy policy.